Abstract
We previously reported a novel kappa opioid receptor antagonist JVA 901, now named venorphin, which was designed as a chimeric construct of a cobra venom tetrapeptide and [D-Ala8]dynorphin A(1–11)NH2 [1]. The N-terminal region of this new peptide exhibits structure-activity relationships (SAR) distinctly different from that of [D-Ala8]dynorphin A(1–11)NH2 [2]. Herein we explore the SAR of the C-terminal region of venorphin.